Tuberculosis associated immune reconstitution inflammatory syndrome in patients infected with HIV: meningitis a potentially life threatening manifestation
© Agarwal et al.; licensee BioMed Central Ltd. 2012
Received: 18 February 2012
Accepted: 8 May 2012
Published: 23 May 2012
Tuberculosis (TB) is the most common co infection in HIV-infected persons in India, requiring concomitant administration of anti TB and antiretroviral therapies. Paradoxical worsening of tuberculosis after anti-retroviral therapy (ART) initiation is frequently seen.
To study the frequency, clinical presentation and outcome of paradoxical tuberculosis associated immune reconstitution inflammatory syndrome (TB-IRIS) in HIV infected patients in a TB hospital in North India.
A retrospective chart review of HIV-infected TB patients on anti-tubercular treatment (ATT) at time of ART initiation over a 3 year period. Medical records were reviewed for clinical manifestations and outcome in patients who developed TB-IRIS.
514 HIV-infected patients were enrolled between January 2006 and December 2008. Thirteen (12.6%) of 103 patients who had received ART and ATT simultaneously developed paradoxical TB-IRIS. Clinical presentations of paradoxical TB-IRIS included new lymphadenopathy (n = 3), increase in size of existing lymphadenopathy (n = 3), worsening of existing pulmonary lesions (n = 2), appearance of new pleural effusion (n = 1) and prolonged high grade fever (n = 2). Four patients developed new tubercular meningitis as manifestation of TB-IRIS. Our cases developed TB-IRIS a median of 15 days after starting ART (IQR 15–36). TB-IRIS patients were older (> 35 years) than those with no IRIS (P = 0.03), but were not distinguishable by CD4 T-cell count, duration of ATT before ART or the outcome of TB treatment. Eight (62%) patients had a complete recovery while 5 (38%) patients with TB-IRIS died, of which majority (n = 3) had meningitis.
Paradoxical TB-IRIS is a frequent problem during concomitant ATT and ART in HIV-TB co infected patients in north India. Meningitis is a potentially life threatening manifestation of TB-IRIS.
Tuberculosis (TB) is the most common co-infection in HIV-infected persons in high burden countries like India . Many HIV patients consequently require concomitant anti-tubercular treatment (ATT) and antiretroviral therapy (ART). Paradoxical worsening of TB after ART initiation is termed as TB associated immune reconstitution inflammatory syndrome (TB-IRIS) as these exaggerated inflammatory responses are attributed to immune recovery. TB-IRIS is characterized by either deterioration of existing lesions (paradoxical TB-IRIS) or the appearance of new disease associated with previously subclinical infection (unmasking TB-IRIS) after ART initiation . These conditions probably reflect rapid restoration of pathogen-specific immune responses with ART.
Paradoxical TB-IRIS has varied clinical presentations. In some cases, it may present as mild lymph node inflammation alone, while in others it may manifest as potentially life threatening complications like meningitis or acute respiratory distress syndrome . In a clinical setting, paradoxical TB-IRIS needs to be differentiated from other complications of ART and HIV infection like drug toxicities, development of new opportunistic infection, failure of treatment and possible non-adherence to treatment. In this paper, we have evaluated the frequency, clinical presentation and outcome of paradoxical TB-IRIS in patients attending an HIV clinic in a referral TB hospital in North India.
This study was a retrospective analysis of prospectively collected data obtained in a structured format from patients with HIV infection and TB disease who were on ATT at time of ART initiation. Detailed case notes were available until the end of ATT, so occurrence of IRIS episode and the time of IRIS development could be accurately analysed.
We reviewed structured patient charts for 103 adult HIV-infected patients, who had active TB and were treated for tuberculosis and HIV disease at the HIV clinic of LRS Institute of TB and Respiratory Diseases, New Delhi, between January 2006 and December 2008.
All patients included for this analysis were adults, had active TB at entry to HIV care at the clinic and were started on ATT as soon as TB was diagnosed. None of them were on antiretroviral therapy at time of TB diagnosis. Baseline (pre-ART) CD4 T-cell counts were done and combination antiretroviral therapy was initiated during ATT, as soon as patient stabilized on ATT, as per the National ART guidelines . Data till outcome of TB treatment was available. Follow-up period till completion of TB treatment was taken for the analysis as TB-IRIS occurs during concomitant TB and ART. End points were defined as occurrence of TB-IRIS, completion of ATT or death/default while on TB treatment. HIV-TB cases who died or defaulted while on ATT alone and could not be initiated on ART were excluded. IRIS episodes not associated with M. tuberculosis infection were not considered in this analysis.
Diagnosis and treatment of TB
TB was diagnosed as per existing WHO and Revised National Tuberculosis Control Program (RNTCP)  guidelines by identification of typical clinical features, isolation of acid fast bacilli (AFB) from a clinical specimen wherever possible, radiological findings and decision to treat for TB. TB was classified either as smear-positive pulmonary TB, smear-negative pulmonary TB, or extra-pulmonary TB. Investigations available for patients included sputum smear microscopy for AFB, mycobacterial culture and drug sensitivity, chest radiology, abdominal ultrasonography, fine needle aspiration for cytology, AFB smear / culture and computed tomography wherever indicated. ATT comprised standard short course regimens available under the RNTCP which consist of rifampicin, isoniazid, pyrazinamide and ethambutol with additional streptomycin in retreatment cases. Outcomes of TB treatment also had been recorded in accordance to the RNTCP guidelines as Cured, Treatment completed, Died, Failure and Defaulted .
Diagnosis of HIV and antiretroviral therapy
HIV infection was diagnosed using three antigenically different rapid kits as per the national HIV testing policy. ART regimens followed WHO and National ART Program guidelines  and comprised efavirenz in combination with either zidovudine or stavudine and lamivudine; the dose of efavirenz for all adult HIV infected patients on ATT co-prescription being 600 mg once a day, in accordance to the national guidelines. CD4 cell counts were determined by flow-cytometry technique using Facs Count machine with Facscount™ reagents (Becton Dickinson, USA). As per Program guidelines, CD4 T cell counts were determined before treatment initiation and every six months thereafter. Plasma HIV viral load testing is not available under the Program for patients on first line ART regimens.
Diagnosis and management of paradoxical TB-IRIS
The paradoxical TB-IRIS cases documented in the records were diagnosed at the time as an initial symptomatic improvement during ATT followed by an exacerbation of symptoms, signs or radiological manifestations of TB after initiation of ART, which was not due to another opportunistic infection, drug adverse effect or ineffective TB treatment . TB–IRIS cases had been diagnosed at the time of presentation of symptoms by a concurrence of opinion of two trained HIV physicians, after exclusion of other causes. Sputum samples of patients who developed pulmonary manifestations of TB-IRIS were sent for AFB culture and sensitivity testing to exclude drug resistant TB. Cases manifesting CNS symptoms had undergone cerebrospinal fluid examination – cytology, biochemical analysis, India ink preparation and smear/culture for AFB. Contrast enhanced CT scans of the brain though not routinely done, were available for all 4 cases with CNS symptoms. TB-IRIS episodes were managed with non-steroidal anti- inflammatory drugs (NSAIDS) and/or steroids, in addition to ATT and ART. Serious cases received in-patient care.
At time of this analysis, the paradoxical TB-IRIS cases documented in the records were also compared to the International Network for the Study of HIV-associated IRIS (INSHI) case definition for paradoxical TB-associated IRIS for resource limited settings published in 2008  . Ten of 13 cases conformed to the criteria recommended by INSHI for paradoxical TB-IRIS. However all criteria could not be met in 3 cases. In one case, the time of occurrence of TB-IRIS was nearly four months as compared to three months specified in the INSHI definitions and in the other two, high grade protracted fever was the only manifestation of IRIS.
This study was approved by the Institutional Review Board of LRS Institute of TB and Respiratory Diseases, New Delhi, an autonomous institute under the Ministry of Health and Family Welfare, GOI.
Continuous data are presented as median and interquartile range (due to extreme values). Due to small sample size, the continuous variables were compared using Mann–Whitney non parametric statistics. Proportions of categorical variables were compared using chi – squared test (univariate analysis). Yates correction was applied for cells with expected frequency less than 5. All tests were 2-tailed and p <0.05 was considered statistically significant.
A total of 514 HIV-infected patients were registered at the HIV clinic of LRS Institute of TB and Respiratory Diseases, New Delhi between January 2006 and December 2008. Of these, 103 patients had received ART and ATT simultaneously and met our inclusion criteria.
Details of patients developing paradoxical TB-IRIS
Baseline CD4 T-cell count (cells/μl)
Site of TB at initial diagnosis
Time between ATT & ART initiation (days)
Clinical/radiological manifestations of paradoxical TB-IRIS
Interval b/w ART and IRIS appearance (days)
Treatment given for IRIS
Outcome of IRIS
Pulmonary TB with mediastinal lymphadenopathy
Increase in size of mediastinal lymph nodes, new pleural effusion
Bilateral pulmonary TB
Painful new abdominal lymphadenopathy (Baseline USG abdomen was normal)
Severe headache, neck rigidity, TB meningitis
Miliary TB with pleural effusion and hilar and cervical lymphadenopathy
Altered sensorium, neck rigidity, TB meningitis
Increase in size of cervical lymph node
Recurrence of fever (high grade, prolonged)
Bilateral pulmonary TB with empyema and abdominal lymphadenopathy
Increased bilateral pulmonary infiltrates
Increase in size of existing cervical lymph node, appearance of new cervical lymph node
Pulmonary TB with abdominal lymphadenopathy
New inguinal lymph node
Severe headache, vomiting, TB meningitis
Extensive bilateral pulmonary TB
Fever, altered sensorium, TB Meningitis
Recurrence of fever (high grade, prolonged)
Pulmonary TB with pleural effusion
Increased bilateral pulmonary infiltrates
Six patients (47%) received out-patient care and seven (54%) required hospitalization. Nine patients (69%) required steroids as they had severe disease manifestations including meningitis, worsening of extensive pulmonary disease and compressive lymphadenopathy. Three patients were prescribed solely NSAIDS. One required surgical drainage of a lymph node abscess.
Eight (62%) of the 13 patients with paradoxical TB-IRIS had a complete recovery while 5 (38%) patients died. Deaths were attributable to meningitis in 3 patients and extensive worsening of bilateral pulmonary infiltrates in the other 2. All five had been hospitalized and started on steroids. The mean CD4 T cell count for the five cases that died was 73 cells/μl (median 25, IQR 41–74). The means of CD4 cell counts of the three meningitis patients and the other two cases that died were 99 cells/μl and 34 cells/μl respectively.
Comparison of patient characteristics and outcome of TB treatment in cases with and without paradoxical TB –IRIS (univariate analysis)
Cases with TB-IRIS (n = 13)
Cases without TB-IRIS (n = 90)
Age, in years
Age > 35 years, n (%)
Baseline CD4 T-cell count (cells/μl)
CD4 T cell count at six months on ART (cells/μl)
142[192–467]* (n = 7)
156 [176–423]* (n = 66)
Male gender, n (%)
Disseminated & extra pulmonary TB, n (%)
Interval between ATT and ART initiation, in days
Interval between ART initiation and appearance of IRIS, in days
Outcome of TB treatment
Successfully treated, n (%) (Bacteriologically Cured & TB Treatment Completed cases)
Treatment failures, n (%) (Bacteriologically positive at five or more months of TB treatment)
Died, n (%) (Death during course of TB treatment)
Defaulted, n (%) (TB treatment discontinued for 2 or more months consecutively after initiation)
Paradoxical TB-IRIS is a clinical entity frequently encountered when ART is initiated in HIV and TB co-infected patients. Understanding of this phenomenon is particularly relevant for HIV clinics in South East Asia and Africa where many patients with active TB enter ART programs [1, 7].
Retrospective and prospective studies have reported that 7- 43% of patients with HIV-TB co-infection develop IRIS . The frequency of TB-IRIS among patients starting ART during ATT in our series (12.6%) is within this range. Our cases developed IRIS a median of 15 days after starting ART (IQR 15–36) (Table 2), which is similar to that reported by other authors. In most patients, TB-IRIS is seen to develop within the first 2–6 weeks [3, 7–10], though symptoms can occur as early as five days after starting ART. Case reports describing development of TB-IRIS after the first three months of ART initiation are infrequent .
Baseline CD4 T cell counts or CD4 T cell recovery after six months of ART were not different between patients who developed TB-IRIS and those who did not. Earlier studies from South India  and Thailand  report similar findings. However, there are cohort studies from South Africa [7, 13] which report a definite association of development of TB-IRIS with low baseline CD4 counts. The reason for this difference is not clear. It may be a reflection of the overall low CD4 counts of the cohort of HIV-TB cases in this analysis.
In our study from North India, we report serious neurologic and pulmonary manifestations of IRIS, with poor outcomes in patients with extensive and disseminated disease. Neurological disease following initiation of ART due to inflammation associated with previously subclinical M. tuberculosis infection in the central nervous system (CNS) is of particular concern . In this study, we report 4 cases (31%) of meningitis TB-IRIS. They were receiving ATT for extensive TB disease, but had no evidence of CNS involvement at time ART initiation. Following development of meningitis, all four patients were hospitalized and received steroids, but three died. The mean CD4 cell count of three meningitis patients who died was higher as compared to the other two paradoxical TB IRIS patients who died (99 vs.34 cells/μl). The published literature on CNS TB IRIS is mostly restricted to a few case reports [14, 15]. A recent prospective case series from South Africa by Pepper et al, with a larger sample size (190 cases of TB IRIS) has reported neurologic TB-IRIS in 23 (12%) cases where also meningitis was the most common manifestation, followed by tuberculoma and myeloradiculopathy. In their study, Pepper et al also describe a low (70%) six month survival for neurologic TB-IRIS cases .
Working under program conditions, our study was limited by non-availability of plasma viral loads. Also the sample size was inadequate to define risk factors for TB IRIS or draw statistical inferences in general. However it is a precise retrospective review of data, especially outcome data, from a referral TB hospital which cares for TB patients referred from all over north India.
In conclusion, similar to other regions of the world, paradoxical TB-IRIS is a frequent problem during concomitant ATT and ART in HIV-TB co infected patients from northern India and mostly occurs during the initial weeks of ART. Meningitis is a potentially life threatening manifestation of TB-IRIS. Future studies in areas with high prevalence of M. tuberculosis infection should therefore address the issue of how patients at risk of developing paradoxical CNS TB-IRIS might be identified.
The authors are grateful to the staff at the ART centre at LRS Institute of TB and RD. We also acknowledge Benjamin Oliver (University of Western Australia) and the Department of Biostatistics at LRS Institute of Tuberculosis and Respiratory Diseases, New Delhi for the statistical analyses.
- Sharma SK, Mohan A, Kadhiravan T: HIV-TB co-infection: epidemiology, diagnosis and management. Indian J Med Res. 2005, 121: 550-567.PubMedGoogle Scholar
- Meintjes G, Lawn SD, Scano G: Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008, 8: 516-523. 10.1016/S1473-3099(08)70184-1PubMed CentralView ArticlePubMedGoogle Scholar
- Price P, Murdoch DM, Agarwal U, Lewin SR, Elliott JH, French MA: Immune restoration diseases reflect diverse immunopathological mechanisms. Clin Microbiol Rev. 2009, 22: 651-663. 10.1128/CMR.00015-09PubMed CentralView ArticlePubMedGoogle Scholar
- National AIDS Control Organization, Govt. of India:Antiretroviral therapy guidelines for HIV infected adult and adolescents including post exposure prophylaxis. New Delhi. 2007Google Scholar
- Central TB Division, Govt. of India: Managing the Revised National Tuberculosis Control Program in your area. New Delhi. 2005Google Scholar
- Colebunders R, John L, Huyst V, Kambugu A, Scano F, Lyen L: Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources. Int J Tuberc Lung Dis. 2006, 10: 946-53.PubMedGoogle Scholar
- Lawn SD, Myer L, Bekker LG, Wood RG: Tuberculosis associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS. 2007, 21: 335-341. 10.1097/QAD.0b013e328011efacView ArticlePubMedGoogle Scholar
- Agarwal U, Kumar A, Behera D: Profile of HIV associated tuberculosis at a tertiary institute in setting of free anti-retroviral therapy. J Assoc Physicians India. 2009, 57: 685-690.PubMedGoogle Scholar
- Kumarasamy N, Chaguturu S, Mayer KH: Incidence of immune reconstitution syndrome in HIV/tuberculosis-co infected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr. 2004, 37: 1574-1576. 10.1097/00126334-200412150-00007View ArticlePubMedGoogle Scholar
- Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA: Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS. 2005, 19: 399-406. 10.1097/01.aids.0000161769.06158.8aView ArticlePubMedGoogle Scholar
- Huyst V, Lynen L, Bottieau E, Zolfo M, Kestens L, Colebunders R: Immune reconstitution inflammatory syndrome in an HIV/TB coinfected patient four years after starting antiretroviral therapy. Acta Clin Belg. 2007, 62: 126-129.View ArticlePubMedGoogle Scholar
- Tieu HV, Ananworanich J, Avihingsanon A: Immunologic markers as predictors of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV and tuberculosis coinfected persons in Thailand. AIDS Res Hum Retroviruses. 2009, 25: 1083-1089. 10.1089/aid.2009.0055PubMed CentralView ArticlePubMedGoogle Scholar
- Murdoch DM, Venter WDF, Feldman C, Rie AV: Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS. 2008, 22: 601-610. 10.1097/QAD.0b013e3282f4a607View ArticlePubMedGoogle Scholar
- Dautremer J, Pacanowski J, Girard PM, Lalande V, Sivignon F, Meynard JL: A new presentation of immune reconstitution inflammatory syndrome followed by a severe paradoxical reaction in an HIV-1-infected patient with tuberculous meningitis. AIDS. 2007, 21: 381-394. 10.1097/QAD.0b013e328011981aView ArticlePubMedGoogle Scholar
- Vidal JE, Cimerman S, Schiavon Nogueira R: Paradoxical reaction during treatment of tuberculous brain abscess in a patient with AIDS. Rev Inst Med Trop Sao Paulo. 2003, 45: 177-178. 10.1590/S0036-46652003000300012View ArticlePubMedGoogle Scholar
- Pepper DJ, Marais S, Maartens G, Rebe K, Morroni C, Rangaka MX: Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis. 2009, 48: e96-e107. 10.1086/598988View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.